EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3.

Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, Zhang S, Zhao S, Xu H, Li M, Gao Z, Fan Y, Xu J, Wang H, Wang S, Qiu J, Wang Q, Guo X, Deng L, Zhang P, Xue H, Li G. · 2022

Read EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. by Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, Zhang S, Zhao S, Xu H, Li M, Gao Z, Fan Y, Xu J, Wang H, Wang S, Qiu J, Wang Q, Guo X, Deng L, Zhang P, Xue H, Li G. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8759291.txt.

Introduction

Pan and co-authors identify a circular RNA, circNEIL3, that drives glioma growth and suppresses immune attack. Gliomas are the most common malignant brain tumors and carry a poor outlook. Circular RNAs are stable, ring-shaped RNAs found in many tumors. Sequencing of tumor and normal tissue flagged this one as raised in glioma.

Levels rose with tumor severity. Tests in cells and animals confirmed that it fuels tumor growth. It protects a known cancer protein from breakdown. Tumor cells also pack it into exosomes and send it to macrophages. Those macrophages then take on an immune-suppressing state. The authors name it a marker and drug target.

Catalog record

CREATORPan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, Zhang S, Zhao S, Xu H, Li M, Gao Z, Fan Y, Xu J, Wang H, Wang S, Qiu J, Wang Q, Guo X, Deng L, Zhang P, Xue H, Li G.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8759291

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3 By Ziwen Pan, Rongrong Zhao, Boyan Li, Yanhua Qi, Wei Qiu, Qindong Guo, Shouji Zhang, Shulin Zhao, Hao Xu, Ming Li, Zijie Gao, Yang Fan Published in: Molecular Cancer DOI: 10.1186/s12943-021-01485-6 ABSTRACT Abstract Background Gliomas are the most common malignant primary brain tumours with a highly immunosuppressive tumour microenvironment (TME) and poor prognosis. Circular RNAs (circRNA), a newly found type of endogenous noncoding RNA, characterized by high stability, abundance, conservation, have been shown to play an important role in the pathophysiological processes and TME remodelling of various tumours. Methods CircRNA sequencing analysis was performed to explore circRNA expression profiles in normal and glioma tissues. The biological function of a novel circRNA, namely, circNEIL3, in glioma development was confirmed both in vitro and in vivo. Mechanistically, RNA pull-down, mass spectrum, RNA immunoprecipitation (RIP), luciferase reporter, and co-immunoprecipitation assays were conducted. Results We identified circNEIL3, which could be cyclized by EWS RNA-binding protein 1(EWSR1), to be upregulated in glioma tissues and to correlate positively with glioma malignant progression. Functionally, we confirmed that circNEIL3 promotes tumorigenesis and carcinogenic progression of glioma in vitro and in vivo. Mechanistically, circNEIL3 stabilizes IGF2BP3 (insulin-like growth factor 2 mRNA binding protein 3) protein, a known oncogenic protein, by preventing HECTD4-mediated ubiquitination. Moreover, circNEIL3 overexpression glioma cells drives macrophage infiltration into the tumour microenvironment (TME). Finally, circNEIL3 is packaged into exosomes by hnRNPA2B1 and transmitted to infiltrated tumour associated macrophages (TAMs), enabling them to acquire immunosuppressive properties by stabilizing IGF2BP3 and in turn promoting glioma progression. Conclusions This work reveals that circNEIL3 plays a nonnegligible multifaceted role in promoting gliomagenesis, malignant progression and macrophage tumour-promoting phenotypes polarization, highlighting that circNEIL3 is a potential prognostic biomarker and therapeutic target in glioma. Supplementary Information The online version contains supplementary material available at 10.1186/s12943-021-01485-6. Keywords: Glioma, circNEIL3, IGF2BP3, Tumour microenvironment, Tumour-associated macrophages, Exosome BACKGROUND Glioma is the most common and aggressive primary malignancy of the central nervous system and has a poor prognosis. Glioblastoma multiforme (GBM) is a kind of brain glioma, with a WHO grade of IV and the highest degree of malignancy [1, 2]. Even if active surgery is combined with radiotherapy and chemotherapy, the treatment effect of glioma is still poor [3, 4]. Thus, it is important to clarify the molecular mechanism of glioma progression to improve the prognosis of patients. Circular RNAs (circRNAs), a special class of noncoding RNAs, do not have a 5′ end cap or a 3′ end poly(A) tail; rather, they form a circular structure by covalent bonds and are characterized by high stability, abundance, and conservation [5, 6]. Mounting evidence has shown that circRNAs play key roles in various types of cancers [7, 8], including glioma [9, 10]. Although there are a large number of circRNAs that appear capable of regulating gliomagenesis, the function of a handful of others remains to be determined. The impact of abnormal glioma-associated signalling is not limited to cancer cells but rather extends to the complex network of interactions with the tumour microenvironment (TME). The function and composition of the glioma TME are influenced by the intrinsic signalling pathways and secretory factors of cancer cells. In turn, cells in the TME can maintain the cancer hallmark by regulating a variety of tumour biological characteristics, including cell proliferation, survival, migration and immune escape [11, 12]. Within the glioma microenvironment, tumour-associated macrophages (TAMs), composed of bone marrow-derived macrophages (BMDMs) and brain-resident microglia (MG), constitute the most abundant cell population in the glioma TME [13, 14] and have been revealed as critical cell components for gliomagenesis and malignant progression [12, 15]. Several studies have shown that exosomes (50–1150 nm), derived from multivesicular bodies (MVBs) that contain proteins, lipids, and nucleic acids, such as miRNAs, lncRNAs, and circRNAs, can act as signalling vehicles with multiple functions in the interaction between glioma cells and TME cells [16, 17]. Mounting evidence has shown that circRNAs are involved in the multifaceted regulation of the TME [18, 19]. However, details on the mechanisms by which circRNAs in exosomes regulate TAMs in glioma have remained elusive until now. Understanding these multifaceted communications between gliomas and TAMs could open new avenues for therapy. In the present study, we identified a circRNA derived from NEIL3, hsa_circ_0001460, named circNEIL3, by analysing the expression profiles of circRNAs in glioma tissues. The expression of circNEIL3, which can be regulated by EWS RNA-binding protein 1 (EWSR1), increased with the increasing grade of gliomas. Functionally, we confirmed that circNEIL3 promoted tumorigenesis and the progression of glioma in vitro and in vivo. Mechanistically, circNEIL3 stabilizes IGF2BP3 protein, a known oncogenic protein, by preventing HECTD4-mediated ubiquitination. Moreover, circNEIL3-overexpressing glioma cells drive macrophage infiltration into the TME by activating YAP1 signalling and secreting CCL2 and LOX, which are strong macrophage chemokines. Finally, circNEIL3 could be packaged into exosomes by hnRNPA2B1 and transmitted to infiltrating TAMs, thereby enabling them to acquire immunosuppressive properties by stabilizing IGF2BP3, in turn promoting glioma progression. Our data thus provide evidence that circNEIL3 may serve as a potential prognostic biomarker and therapeutic target in glioma. MATERIALS AND METHODS Patient specimens and public patient cohorts Thirty-nine human glioma tissues and 8 NBTs for circRNA sequencing and RNA sequencing were obtained from patients admitted to Qilu Hospital from November 2017 to October 2019. All participants provided written informed consent, and the study was approved by the Ethics Committee on Scientific Research of Shandong University Qilu Hospital (approval number: KYLL-2018-324). The detailed clinicopathological characteristics are described in Additional file Table S8. The RNA-seq transcriptome data and corresponding clinicopathological parameters of the TCGA glioma dataset were obtained from the TCGA database (http://cancergenome.nih.gov/). The CGGA RNA-seq dataset and the corresponding clinicopathological parameters were obtained from the CGGA database (http://www.cgga.org.cn/). The circRNA sequencing and mRNA sequencing data of our local samples have been deposited in the Genome Sequence Archive (GSA) under accession number CRA002339, and data were released when the paper was published. The processed data are available from the corresponding author upon reasonable request. Cell lines and culture Human glioma cell lines (A172 and U251) were purchased from the Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle medium (DMEM; Thermo Fisher Scientific; USA) supplemented with 10% foetal bovine serum (FBS; Gibco; USA). All patient-derived GSC cell lines and neural progenitor cells (NPCs) were kindly donated by Dr. Frederick F Lang and Dr. Krishna P.L. Bhat (The University of Texas, M.D. Anderson Cancer Center, Houston, TX) and cultured in DMEM/F12 (10,565,018; Gibco, USA) supplemented with 2% B-27 without serum supplement (17,504,044; Gibco, USA), 20 ng/mL human recombinant EGF (236-EG; R&D Systems, USA) and 20 ng/mL human recombinant bFGF (233-FB; R&D Systems). All cell lines were maintained in a humidified chamber containing 5% CO2 at 37 °C. Quantitative real-time PCR (qRT-PCR) Total RNA was extracted from glioma cells using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). Reverse transcription was performed using 1 μg of total RNA and the High Capacity cDNA Reverse Transcription Kit (Toyobo, FSQ-101, Shanghai, China) according to the manufacturer’s protocol. An Mx-3000P Quantitative PCR System (Applied Biosystems, Foster City, USA) was used for qRT-PCR. The expression of GAPDH was used as a control to calibrate the

Read the complete text